News
Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are ...
9h
In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...
Immunotherapy uses a person's own immune system to fight cancer. Immune checkpoint inhibitors are one class of immunotherapy ...
Amplia Therapeutics and Immutep have released clinical trial results that promise more effective treatments for pancreatic and lung cancers ...
Like cancer, placental cells multiply rapidly, invade tissues, and evade destruction by the immune system, but maternal ...
What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...
A new study of 18,932 metastatic colorectal cancer patients reveals that microsatellite instability, albumin levels, and ...
Smith, Ph.D. and Ramiro Guerrero, JD, LL.M., purchased common stock and warrants in the Company’s private placement offering ...
UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus” or the "Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer ...
A dedicated onconephrology service at Brigham and Women’s Hospital has improved kidney outcomes in patients treated for ...
KL Krems study shows that higher radiation doses in lung cancer treatment carry no added risk of inflammation – and may improve survival: Krems Wednesday, May 14, 2025, 14:00 Hr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback